Literature DB >> 26497347

The management of prostatic obstruction with urethral stents.

Charles C Peyton1, Gopal H Badlani.   

Abstract

INTRODUCTION: Elderly men with multiple comorbidities may be unfit to undergo surgical management of benign prostatic obstruction (BPO). Permanent and temporary prostatic stents have been developed as an alternative to chronic indwelling catheters in men unfit for surgery.
MATERIALS AND METHODS: Herein we review the past and present literature on the role and effectiveness of prostatic stents in the treatment of BPO.
RESULTS: Permanent prostatic stents have largely been abandoned in North America due to unfavorable outcomes and improved technologies to allow for treatment of BPO. Currently, the temporary Spanner stent is the only available stent on the market, but its effectiveness has mostly been documented for temporary relief of tissue edema following minimal invasive ablative treatments for BPO.
CONCLUSIONS: The advent of well-tolerated surgical treatments for BPO (KTP laser vaporization, bipolar TURP, urethral lift devices) has diminished the need for permanent prostatic stents. The temporary Spanner stent is an alternative to urethral catheter, but requires adequate detrusor function and can cause irritative symptoms.

Entities:  

Mesh:

Year:  2015        PMID: 26497347

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  2 in total

1.  Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study.

Authors:  Gregor Kadner; Massimo Valerio; Ioannis Giannakis; Arya Manit; Nicolaas Lumen; Brian S H Ho; Sergio Alonso; Claude Schulman; Neil Barber; Daniele Amparore; Francesco Porpiglia
Journal:  World J Urol       Date:  2020-03-02       Impact factor: 4.226

2.  The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction.

Authors:  Claus G Roehrborn; Peter T Chin; Henry H Woo
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-08-06       Impact factor: 5.455

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.